The week in health tech, explained in plain English.Get the free newsletter →
November 10, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

GSK to Buy Cancer Drugmaker Nuvalent for $10.6 Billion

GSK is buying Nuvalent for $10.6 billion, a significant bet on targeted cancer therapies, STAT News reports. The acquisition gives GSK control of Nuvalent's late-stage lung cancer candidates, including zidesamtinib and neladalkib, which are designed to hit specific genetic drivers of disease while limiting the side effects that plague older treatments.

The move fits a clear industry pattern. Large drugmakers facing patent expirations on blockbuster products are spending heavily to acquire promising clinical-stage assets rather than build them in-house. Targeted oncology has become a favored hunting ground because precision drugs can command premium pricing and serve patient populations defined by molecular testing.

For GSK, the deal deepens an oncology portfolio it has worked to rebuild after earlier divestitures. For the broader market, it signals continued appetite for sizable, pipeline-focused acquisitions. Investors should watch how regulators view the price and how quickly GSK can advance Nuvalent's candidates toward approval, where commercial returns ultimately hinge on trial outcomes.

Sources

More in Finance

Finance

Novartis Lp(a) Drug Lowers Risk Marker but Fails on Outcomes

Novartis's pelacarsen lowered the cardiovascular risk marker Lp(a) but failed to reduce heart attacks or strokes, undermining a major industry strategy.

Why it matters: A failed outcomes trial for a leading Lp(a) drug threatens billions in cardiovascular research built on the assumption that lowering the marker prevents events.

Finance

Novo's Ziltivekimab Flops, But Cardiologists Stay Bullish

Novo Nordisk's ziltivekimab missed in the ZEUS cardiovascular trial, but cardiologists say the anti-inflammatory approach to heart disease remains valid.

Why it matters: Anti-inflammatory therapy is one of the biggest bets in cardiovascular medicine, and how the field reacts to a high-profile failure shapes billions in future R&D.

Finance

Pennsylvania Revokes Sharon Regional Hospital License

Pennsylvania revoked Sharon Regional Medical Center's license and ordered it to close after its utility moved to cut power over an unpaid bill.

Why it matters: An unpaid electricity bill forcing a hospital's closure shows how severe financial distress can abruptly cut off care for an entire community.